Keio Innovation Initiative

Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Aeterlink is a developer of advanced wireless power transfer technology aimed at eliminating the need for wires in various applications. The company specializes in creating wireless devices that can be applied across multiple fields, including factory automation, robotics, smart homes, and medicine. By enabling the wireless transmission of power over distances, Aeterlink's innovations enhance efficiency, sustainability, and safety in industries, allowing for greater flexibility in device placement and reducing the risks associated with traditional wiring. Their technology represents a significant step toward a digital world that operates without the constraints of physical connections.

JiMED is a company specializing in wireless embedded brain-computer interface (BCI) systems that monitor brain activity. It offers a wireless implantable BCI system that utilizes an implanted device in conjunction with artificial intelligence to interpret brain signals. This innovative technology allows individuals with ALS to control the device through thought, significantly enhancing their ability to communicate and improve their quality of life.

Neusignal Therapeutics is a medical company focused on developing therapeutic medicines for dementia and various psychiatric illnesses. The company specializes in the research and development of small molecule drugs aimed at addressing brain diseases and overcoming challenges associated with central nervous system disorders. By concentrating on innovative therapeutic agents, Neusignal Therapeutics seeks to improve the quality of life for patients suffering from these conditions, aiming to resolve a range of issues related to brain health.

BlueWX is a software company that develops predictive content services that supports in forecasting, and weather analysis.

DigitalArchi is a manufacturing company that offers interior parts, fixtures, concrete formwork for construction, recycle and sells plastic.

Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company focused on creating innovative antibody-based therapies for cancer treatment. Utilizing its proprietary Eumbody System™, the company develops and detects single-chain variable fragment (scFv) product candidates that specifically target oncology-related pathways. These therapies are designed to enhance immune-cell function and improve the proliferation capacity and longevity of CAR-T cells, allowing for better patient responses to advanced tumors while minimizing side effects. Optieum Biotechnologies aims to provide effective, life-changing treatments for patients facing severe diseases.

Japan Carbon Cycle Lab is a technology company that focuses on the research and development of CO2 capture and recycling techniques.

elleThermo focuses on the development of Semiconductor-Sensitised Thermal Cells (STCs), a technology that converts unused waste heat into electricity. This innovative energy conversion method targets heat sources above room temperature, allowing for efficient energy generation. The company aims to provide a stable power generation system that integrates with renewable energy sources, catering to various electrical appliances and equipment. By leveraging STC technology, elleThermo seeks to address energy efficiency challenges and optimize space utilization for users, contributing to the advancement of new energy solutions.

Nihon Agri, Inc. is a Tokyo-based company founded in 2016 that specializes in the export and coordination of Japanese agricultural products. The company focuses on overcoming challenges faced by Japanese farmers in exporting their goods, including issues related to pricing, communication, and logistics. By providing a range of services such as in-house farm production, production guidance, material import, and branding, Nihon Agri aims to enhance overseas sales channels for Japanese agricultural products. The company seeks to meet the growing demand from global consumers for high-quality Japanese produce while addressing the unmet needs of local farmers aspiring to reach international markets.

Aeterlink is a developer of advanced wireless power transfer technology aimed at eliminating the need for wires in various applications. The company specializes in creating wireless devices that can be applied across multiple fields, including factory automation, robotics, smart homes, and medicine. By enabling the wireless transmission of power over distances, Aeterlink's innovations enhance efficiency, sustainability, and safety in industries, allowing for greater flexibility in device placement and reducing the risks associated with traditional wiring. Their technology represents a significant step toward a digital world that operates without the constraints of physical connections.

PURMX is a pharmaceutical company focused on developing RNA nucleic acid medicines aimed at treating intractable diseases, particularly malignant pleural mesothelioma. The company specializes in creating innovative nucleic acid drugs that utilize small ribonucleic acid to address deficiencies in cells. By providing targeted therapies for cancer treatment, PURMX aims to improve patient outcomes and support healthcare professionals in their efforts to manage complex medical conditions.

Developer of a healthcare technology designed to replace the traditional way of treating cancer treatment. The company aims to transform the traditional therapeutic into a next-generation therapy for cancer diseases by maximizing the drug potency with minimum toxicity, helping the healthcare sector to overcome systemic toxicity and exhibiting strong anti-tumor efficacy in various tumor models both as monotherapy and in combination with immune checkpoint inhibitors.

newmo delivers sustainable local public transportation create a user experience (UX) that people may utilize with peace of mind and comfort.

Axelspace Corporation is a Tokyo-based company specializing in the design, manufacture, and sale of micro-satellites and their components. Founded in 2008, Axelspace develops various micro-satellite projects, including GRUS, a remote-sensing satellite aimed at creating an Earth observation constellation, and WNISAT-1, which monitors sea ice distribution to enhance vessel navigation in polar regions. The company also produces essential micro-satellite components such as sensors for attitude determination, GPS receivers for positioning, and high-speed data transmitters. Axelspace's mission includes constructing a global monitoring platform that provides daily coverage at a low cost, ensuring clients have access to high-quality satellite imagery. In addition to its satellite technology, Axelspace arranges satellite launches and offers operational support, contributing to a broader understanding and utilization of micro-satellites in various applications.

Hedgehog MedTech is a medical company dedicated to developing digital therapeutics, specifically aimed at treating headaches and migraines. The firm offers a smartphone application that employs cognitive-behavioral therapy techniques to help users manage their symptoms. By analyzing and improving users' behavioral patterns, the app provides personalized treatment options, bridging the gap between daily life and medical care. This innovative approach allows patients to engage with their treatment in a convenient and accessible manner, enhancing their overall well-being.

Nanofiber Quantum Technologies is a research and manufacturing company focused on developing hardware for quantum communications. The company specializes in creating quantum computers that utilize nanofibers and advanced engineering techniques. Its primary areas of expertise include quantum cryptography and quantum communications, aiming to integrate these technologies into practical applications for societal benefit. By providing clients with innovative quantum networks, Nanofiber Quantum Technologies is advancing the field of quantum science and facilitating its implementation in various sectors.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

Hedgehog MedTech is a medical company dedicated to developing digital therapeutics, specifically aimed at treating headaches and migraines. The firm offers a smartphone application that employs cognitive-behavioral therapy techniques to help users manage their symptoms. By analyzing and improving users' behavioral patterns, the app provides personalized treatment options, bridging the gap between daily life and medical care. This innovative approach allows patients to engage with their treatment in a convenient and accessible manner, enhancing their overall well-being.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

LIFESCAPES is a research and manufacturing company specializing in brain-computer interface equipment, particularly for neurorehabilitation. The company's technology focuses on aiding stroke patients by enhancing brain plasticity, which allows individuals to overcome limitations and improve their quality of life. LIFESCAPES' devices are designed to extract and analyze brain-wave data in real-time, monitoring the activity of the functional compensation circuits in stroke patients. This innovative approach enables healthcare professionals to assist patients in regaining movement and addressing movement disorders, ultimately facilitating a more normal and fulfilling life for those affected.

K Pharma is engaged in the research, development, manufacturing, and marketing of pharmaceuticals, with a particular focus on neuro regenerative medicine. The company utilizes induced pluripotent stem (iPS) cell technology to create innovative treatments for neurological conditions, including cerebral infarction and spinal cord injury. By combining advanced drug discovery methods with a commitment to developing medical products, K Pharma aims to address significant unmet needs in the field of regenerative medicine.

FingerVision is a company focused on developing advanced sensing devices and robotic technologies aimed at enhancing the capabilities of robots and machines. By integrating visual and haptic technology derived from academic research, FingerVision aims to broaden the application areas of robotics. The company's innovations improve the dexterity and functionality of robotic hands, enabling them to perform tasks traditionally handled by humans. This advancement allows industries to automate processes such as pick-and-place operations, leading to increased efficiency and reduced labor costs, while also addressing various social challenges.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

Cellusion Inc. is a Tokyo-based regenerative medicine company specializing in the research and development, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells aimed at treating bullous keratopathy. Founded in 2015, Cellusion focuses on providing innovative solutions for cell transplantation, utilizing a mass culture system for corneal endothelial cells derived from iPS cells. This approach allows healthcare professionals to improve vision in patients suffering from bullous keratopathy by injecting the cell substitutes, which replace damaged corneal tissue, thereby enhancing the quality of life for affected individuals.

Luxonus is a medical device manufacturing company specializing in photoacoustic technology aimed at early disease detection and diagnosis. The company has developed an advanced imaging device that utilizes optical ultrasonic technology, which combines light and ultrasonic waves to create ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This innovative approach allows for safe and easy imaging without exposure, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and overall health conditions before and after illness.

Grace Imaging specializes in advanced fatigue measurement services that utilize lactate sensing in sweat and MRI technologies. The company has developed a device designed to measure lactic acid concentration in sweat, allowing for precise fatigue analysis. By integrating sweat lactate sensors and MRI techniques, Grace Imaging offers users insights into exercise load and muscle changes, enhancing the understanding of athletic performance and recovery.

Heartseed Inc., founded in 2015 and located in Tokyo, Japan, focuses on developing myocardial regeneration medicine using induced pluripotent stem (iPS) cells. The company is dedicated to advancing the clinical application of regenerative medicine for heart disease, specifically through the development and commercialization of iPS cell-derived cardiomyocyte replacement therapy aimed at treating advanced heart failure. Heartseed's mission is to transform heart disease treatment by pioneering innovative solutions in myocardial regeneration.

Metagen Therapeutics is a drug discovery and development company that harnesses the potential of microbiome science to advance medical innovations. As a joint venture between Fast Track Initiative Co., Ltd. and Keio Innovation Co., Ltd., it focuses on utilizing the gut microbiome's capabilities to create new treatments applicable across pharmaceutical, healthcare, and functional food sectors. The company's mission is to contribute to disease prevention and cure through its research and development efforts, aiming to enhance patient outcomes and promote overall health.

B dot Medical focuses on the development of ultra-compact proton beam cancer therapy equipment. The company designs a system that utilizes advanced radiotherapy techniques to accurately target tumors located deep within the body. This precision reduces damage to surrounding healthy tissues and organs, enhancing the effectiveness of cancer treatments. By providing features such as scanning irradiation, magnet design, gantry, and treatment couch, B dot Medical aims to offer a more accessible and cost-effective solution for proton cancer therapy, challenging traditional approaches to cancer treatment.

Connect Japan is developing services that connect people.

AdipoSeeds is a biotechnology company focused on addressing the global shortage of platelets by developing an innovative platelet-making system. The company utilizes mesenchymal stem cells to create platelets without the need for complex and costly gene transfer techniques. By pioneering a new blood supply system, AdipoSeeds aims to provide a cost-effective and safe solution for platelet-related treatments. Their technology offers fat-derived platelets that can be utilized in various applications, including blood products and wound care medicine, ultimately contributing to improved healthcare outcomes.

Skygate Technologies Inc., founded in 2020 and based in Tokyo, Japan, specializes in designing and developing a cloud ground station platform that facilitates communication between satellites and the Earth. The company aims to democratize space-to-earth communication and support the growth of the NewSpace ecosystem. By providing a ground station as a service, Skygate Technologies optimizes operations for low Earth orbit satellites, incorporating features such as a unified antenna specification and software radio for automatic satellite acquisition and tracking. Their mission, encapsulated in the motto "Make Space accessible on the Web," emphasizes their commitment to integrating satellite communication into web architecture, thereby enhancing accessibility and efficiency in data transmission from observation satellites.

Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.

APB specializes in the research, development, manufacturing, and sales of advanced battery technologies, focusing on lithium-ion and all-polymer batteries. The company utilizes innovative polymer materials instead of traditional metals for current collectors, enhancing the energy density and performance of its products. APB's batteries are designed for various applications, including consumer electronics, automotive use, and large-scale energy storage systems, particularly for renewable energy sources like wind and solar power. By employing a polymer resin and a bipolar structure, APB aims to provide high-flexibility, low-cost, and safe energy solutions that meet the growing demands of distributed energy resources.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company focuses on the research and development of hepatocyte growth factor (HGF) and its applications in treating various medical conditions. Kringle Pharma's HGF products aim to promote regenerative healing in liver cells and other organs, addressing acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scars. Additionally, the company develops NK4, a bi-functional molecule that serves as an HGF antagonist, inhibiting tumor cell invasion and metastasis while exhibiting antiangiogenic properties. Kringle Pharma's pipeline includes recombinant human HGF for acute renal failure and skin ulcers, as well as NK4-based therapies for cancer treatment.

Cellusion Inc. is a Tokyo-based regenerative medicine company specializing in the research and development, manufacturing, and sales of induced pluripotent stem cell-derived corneal endothelial cells aimed at treating bullous keratopathy. Founded in 2015, Cellusion focuses on providing innovative solutions for cell transplantation, utilizing a mass culture system for corneal endothelial cells derived from iPS cells. This approach allows healthcare professionals to improve vision in patients suffering from bullous keratopathy by injecting the cell substitutes, which replace damaged corneal tissue, thereby enhancing the quality of life for affected individuals.

Luxonus is a medical device manufacturing company specializing in photoacoustic technology aimed at early disease detection and diagnosis. The company has developed an advanced imaging device that utilizes optical ultrasonic technology, which combines light and ultrasonic waves to create ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This innovative approach allows for safe and easy imaging without exposure, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and overall health conditions before and after illness.

Synspective Inc., based in Tokyo, Japan, specializes in satellite data technology that leverages synthetic aperture radar (SAR) satellite constellations, big data, and machine learning. The company provides remote sensing and satellite imagery services, utilizing small-sized SAR satellites capable of monitoring human activity across extensive areas, irrespective of time or weather conditions. Its offerings cater to various sectors, including urban design, infrastructure, energy, insurance, and finance, while also supporting government agencies in their data needs. By integrating advanced satellite data with analytical tools, Synspective aims to assist clients in achieving sustainable development and resilient urban growth.

Motion Lib, Inc., founded in 2016 and based in Kawasaki, Japan, specializes in haptic technology aimed at enhancing collaboration between humans and robots. The company, originally known as Undou Sekkei Kenkyuusho Limited until its rebranding in April 2017, has developed a specialized chip that estimates and calculates the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovation enables machines to interact more effectively with their environment, expanding their operational capabilities and contributing to increased productivity in various sectors.

Instalimb, Inc. is a Tokyo-based company focused on developing low-cost prosthetics and orthotics through advanced technology, specifically 3D printing and machine learning. As a pioneer in the field, Instalimb utilizes 3D-CAD and modeling software equipped with algorithms that optimize design and production processes. This innovative approach significantly reduces the cost of prosthetics to approximately one-tenth of traditional methods and shortens delivery times, allowing amputees to access high-quality, customized prosthetic solutions more quickly and affordably.

Xenodata Lab, Co., Ltd., founded in 2012 and based in Tokyo, Japan, specializes in artificial intelligence-driven data analysis. The company develops a platform that transforms unstructured data from financial reports into structured, table-format data, enhancing accuracy and accessibility for users. By focusing on economic forecasts and financial document analysis, Xenodata Lab enables businesses to effectively interpret and utilize information following financial results announcements. The company aims to advance the financial industry through innovative technology and the efficient processing of data, emphasizing the potential of AI to enhance human decision-making in this sector.

Luxonus is a medical device manufacturing company specializing in photoacoustic technology aimed at early disease detection and diagnosis. The company has developed an advanced imaging device that utilizes optical ultrasonic technology, which combines light and ultrasonic waves to create ultra-high-resolution three-dimensional images of blood vessels and lymphatic vessels. This innovative approach allows for safe and easy imaging without exposure, providing healthcare professionals with a comprehensive understanding of disease onset, healing processes, and overall health conditions before and after illness.

Himuka AM Pharma Corp. is a pharmaceutical company based in Miyazaki City, Japan, founded in February 2017. The company focuses on the research, development, and discovery of drug candidates derived from the bioactive peptide adrenomedullin (AM), which was initially discovered at the University of Miyazaki. Himuka AM Pharma aims to create derivatives of adrenomedullin that contribute to mucosal healing and clinical remission, addressing significant unmet medical needs in healthcare.

BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.

CureApp, Inc., founded in 2014 and based in Tokyo, Japan, specializes in developing mobile applications aimed at treating various health conditions, particularly nicotine addiction. The company's flagship product, a nicotine addiction treatment app, was launched in February 2015 in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp is recognized as a prominent player in the digital health sector, focusing on applications that exhibit therapeutic effects against diseases. The company is actively conducting clinical trials to validate the efficacy of its applications. Additionally, CureApp's medical treatment platform allows users to keep daily activity logs, which are analyzed to identify triggers exacerbating their conditions. This technology enables patients to receive personalized guidance in managing lifestyle diseases, addressing health issues that are typically not managed by conventional medications or devices.

Tsubota Laboratory is involved in the research and development of pharmaceuticals and medical devices aimed at preventing and treating myopia, dry eye, presbyopia, and other eye-related conditions. The organization focuses on creating evidence-based solutions to address these eye diseases and systemic health issues.

Institution for a Global Society specializes in providing innovative assessment solutions designed for educational institutions and businesses. Its offerings include GROW Academy, DxGROW, Ai GROW, and GROW360, which aim to facilitate seamless and unbiased evaluation processes. The organization employs ethical technology to foster a sustainable learning and development environment for individuals throughout their lives. Additionally, it focuses on people analytics, helping organizations identify, recruit, and develop human capital effectively. Its predictive analytics software has gained traction among various entities, including multinational corporations, government agencies, and international institutions, highlighting its commitment to enhancing human resource capabilities and promoting lifelong learning.

IDAC Theranostics, Inc. is a biotechnology company based in Tokyo, Japan, that focuses on the research, development, and production of pharmaceutical products aimed at treating various conditions, including cancer, graft-versus-host disease (GVHD), and inflammatory diseases. Founded in 2012, the company is dedicated to creating drug therapies for diseases that typically require only symptomatic treatment. IDAC collaborates with academic institutions and pharmaceutical companies in Japan and abroad to advance its research efforts. Through these partnerships, IDAC Theranostics aims to develop effective solutions for patients with unmet medical needs, enhancing the capabilities of healthcare providers and the pharmaceutical industry.

Motion Lib, Inc., founded in 2016 and based in Kawasaki, Japan, specializes in haptic technology aimed at enhancing collaboration between humans and robots. The company, originally known as Undou Sekkei Kenkyuusho Limited until its rebranding in April 2017, has developed a specialized chip that estimates and calculates the repulsive force experienced when objects are touched, based on the load force applied to robotic motors. This innovation enables machines to interact more effectively with their environment, expanding their operational capabilities and contributing to increased productivity in various sectors.

Generic Solution Corporation, founded in 2006 and based in Tokyo, Japan, specializes in software distribution services and offers a range of data analytics and artificial intelligence solutions. The company provides GS8 software, which focuses on information retrieval and machine learning, as well as distributed computing services, data model design, and comprehensive data analysis. By leveraging large-scale data analytic techniques, Generic Solution aims to assist its clients in organizing and analyzing complex information, thereby enabling them to set profit targets and achieve measurable outcomes. The company's commitment to delivering effective solutions helps enhance its customers' competitiveness in the market.

BONX Inc. specializes in the design and development of wearable communication devices tailored for outdoor sports enthusiasts. Founded in 2014 and based in Tokyo, Japan, the company offers the BONX Grip, a Bluetooth earpiece that enables group conversations, music streaming, and phone calls. This device is particularly suited for activities such as snowboarding, cycling, stand-up paddleboarding, and fishing, featuring water and shockproof capabilities to withstand the rigors of outdoor use. BONX sells its products online, providing athletes with a reliable means to stay connected with friends while engaging in leisure and sporting activities.

CureApp, Inc., founded in 2014 and based in Tokyo, Japan, specializes in developing mobile applications aimed at treating various health conditions, particularly nicotine addiction. The company's flagship product, a nicotine addiction treatment app, was launched in February 2015 in collaboration with the Division of Pulmonary Medicine at Keio University’s School of Medicine. CureApp is recognized as a prominent player in the digital health sector, focusing on applications that exhibit therapeutic effects against diseases. The company is actively conducting clinical trials to validate the efficacy of its applications. Additionally, CureApp's medical treatment platform allows users to keep daily activity logs, which are analyzed to identify triggers exacerbating their conditions. This technology enables patients to receive personalized guidance in managing lifestyle diseases, addressing health issues that are typically not managed by conventional medications or devices.

Quan Inc. is a Tokyo-based company that specializes in developing characters and game content for smartphone applications and web platforms. Established in 2011, the company offers a diverse portfolio of over 500 characters, including popular figures such as Betakkuma, Sugar Cubs, and Mr. Egg, which are used in chat applications and mobile services primarily in Japan and Southeast Asia. In addition to character development, Quan Inc. creates content for social and casual games, as well as keyboard and sticker applications. The company also provides global content distribution services and engages in public relations and advertising, focusing on market research, translation, and game management.

AdipoSeeds is a biotechnology company focused on addressing the global shortage of platelets by developing an innovative platelet-making system. The company utilizes mesenchymal stem cells to create platelets without the need for complex and costly gene transfer techniques. By pioneering a new blood supply system, AdipoSeeds aims to provide a cost-effective and safe solution for platelet-related treatments. Their technology offers fat-derived platelets that can be utilized in various applications, including blood products and wound care medicine, ultimately contributing to improved healthcare outcomes.

Kringle Pharma, Inc. is a biopharmaceutical company based in Ibaraki, Japan, founded in 2001. The company focuses on the research and development of hepatocyte growth factor (HGF) and its applications in treating various medical conditions. Kringle Pharma's HGF products aim to promote regenerative healing in liver cells and other organs, addressing acute spinal cord injury, amyotrophic lateral sclerosis (ALS), acute kidney injury, and vocal fold scars. Additionally, the company develops NK4, a bi-functional molecule that serves as an HGF antagonist, inhibiting tumor cell invasion and metastasis while exhibiting antiangiogenic properties. Kringle Pharma's pipeline includes recombinant human HGF for acute renal failure and skin ulcers, as well as NK4-based therapies for cancer treatment.

SENSY INC., established in November 2011 and headquartered in Tokyo, Japan, specializes in artificial intelligence technology focused on understanding human sensibilities. The company develops a personal AI that learns the unique sensitivities of individual users, facilitating transformative experiences across various aspects of life. SENSY's technology employs natural language processing to analyze diverse data sources, including images, text, music, and taste preferences. This enables businesses to implement personalized marketing strategies by allowing the AI to predict customer behaviors, such as visit timing and responses to promotions. In addition to consumer applications, SENSY provides support for launching new business-related services, catering to both business-to-consumer and business-to-business markets.